Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
12
CELU Quote, Financials, Valuation and Earnings
Last price:
$2.04
Seasonality move
:
36.82%
Day range:
$2.04 - $2.28
52-week range:
$1.30 - $7.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.98x
P/B ratio:
2.91x
Volume:
98K
Avg. volume:
383.7K
1-year change:
32.23%
Market cap:
$50.4M
Revenue:
$22.8M
EPS (TTM):
-$1.57
Analysts' Opinion
-
Consensus RatingCelularity has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Celularity has an estimated upside of 1016.07% from its current price of $2.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.24.
Fair Value
-
According to the consensus of 0 analysts, Celularity has 1016.07% upside to fair value with a price target of -- per share.
CELU vs. S&P 500
-
Over the past 5 trading days, Celularity has underperformed the S&P 500 by -- suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Celularity does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Celularity has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Celularity reported revenues of $9.3M.
Earnings Growth
-
Celularity earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Celularity reported earnings per share of -$0.73.
Enterprise value:
92.8M
EV / Invested capital:
1.55x
Price / LTM sales:
0.98x
EV / EBIT:
--
EV / Revenue:
1.93x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-7.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$30.9M
Return On Assets:
-24.71%
Net Income Margin (TTM):
-72.72%
Return On Equity:
-118.79%
Return On Invested Capital:
-50.77%
Operating Margin:
-124%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $18.7M | $14.8M | $48.2M | $3.8M | $9.3M | |
| Gross Profit | -$376K | $3.1M | $30.9M | $184K | $5.4M | |
| Operating Income | -$154.8M | -$97.4M | -$39.9M | -$16.3M | -$11.5M | |
| EBITDA | -$3.9M | -$169.6M | -$21.6M | -$90.6M | -$12.5M | |
| Diluted EPS | -$1.60 | -$10.17 | -$1.57 | -$4.98 | -$0.73 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $91.3M | $63.1M | $16.5M | $14.5M | |
| Total Assets | -- | $448.3M | $437.1M | $157.2M | $128.8M | |
| Current Liabilities | -- | $29.2M | $69.2M | $84.6M | $76.2M | |
| Total Liabilities | -- | $352.1M | $272.9M | $126.9M | $111.6M | |
| Total Equity | -- | $96.2M | $164.2M | $30.2M | $17.3M | |
| Total Debt | -- | -- | $39.3M | $35M | $42.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$140.3M | -$63.9M | -$12.3M | -$8.3M | -$144K | |
| Cash From Investing | -$6.8M | -$4.2M | $1.5M | -$228K | -$35K | |
| Cash From Financing | $117.1M | $25.8M | $6M | $5.7M | -$79K | |
| Free Cash Flow | -$147.1M | -$68.2M | -$13M | -$8.6M | -$179K | |
CELU
Sector
Market Cap
$50.4M
$45.9M
Price % of 52-Week High
28.11%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-11.88%
-0.6%
1-Year Price Total Return
32.23%
-32.15%
Beta (5-Year)
0.642
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.24
200-day SMA
Sell
Level
$3.09
Bollinger Bands (100)
Sell
Level
2.11 - 3.07
Chaikin Money Flow
Sell
Level
-75.3M
20-day SMA
Buy
Level
$2.23
Relative Strength Index (RSI14)
Sell
Level
47.26
ADX Line
Sell
Level
21.8
Williams %R
Neutral
Level
-66.6611
50-day SMA
Sell
Level
$2.34
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
47M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.5814)
Sell
CA Score
(Annual)
Level (-3.9054)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.9629)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Stock Forecast FAQ
In the current month, CELU has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CELU average analyst price target in the past 3 months is --.
-
Where Will Celularity Stock Be In 1 Year?
According to analysts, the consensus estimate is that Celularity share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Celularity?
Analysts are divided on their view about Celularity share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Celularity is a Sell and believe this share price will drop from its current level to --.
-
What Is Celularity's Price Target?
The price target for Celularity over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CELU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Celularity is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CELU?
You can purchase shares of Celularity via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Celularity shares.
-
What Is The Celularity Share Price Today?
Celularity was last trading at $2.04 per share. This represents the most recent stock quote for Celularity. Yesterday, Celularity closed at $2.24 per share.
-
How To Buy Celularity Stock Online?
In order to purchase Celularity stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
